Young Man with Rare Disease Urges Patient-Centered FDA Leadership

Elijah Stacy, a 25-year-old living with Duchenne muscular dystrophy (DMD), has voiced his urgent need for a Food and Drug Administration (FDA) commissioner who prioritizes patient perspectives. DMD is a progressive disease that significantly shortens life expectancy, with individuals rarely expected to live past 25. Stacy, who has outlived typical expectations for his condition, is closely watching the Senate confirmation hearing for Dr. Heidi Overton, the nominee to lead the FDA.

For patients like Stacy, who live with rare diseases, the FDA commissioner's decisions directly impact treatment options and available time. He stressed that while he respects scientific rigor, the agency often overlooks a critical question: who decides how much risk a patient is willing to accept? Stacy argues that when a patient and their physician understand the risks and there is real evidence supporting a treatment, regulators should not be the final arbiters.

The existing Right to Try Act, signed into law by President Trump in 2018, affirmed that patients facing life-threatening diseases should not be passive observers when approved options are exhausted. Stacy views this as a starting point for a more patient-centered FDA culture, a principle he believes should extend to the agency's evaluation of evidence, risk, urgency, and access for rare disease patients. He pointed to the proposed Right to Try 2.0 legislation by Senator Ron Johnson and Representative Diana Harshbarger as a continuation of this patient-focused approach, particularly for individualized treatments that may not fit traditional approval models.

Stacy highlighted the FDA's accelerated approval pathway, which acknowledges that delays can be detrimental for patients with serious, life-threatening diseases. He noted that this pathway has been utilized for multiple DMD treatments. However, he emphasized that waiting is never neutral for those with DMD, as each year can bring further loss of strength and independence. He also shared his brother's experience of navigating the challenges of accessing treatments, including traveling long distances for clinical trials, which is particularly difficult when dealing with a debilitating illness.

Stacy called for the next FDA commissioner to work collaboratively with patients, physicians, and rare disease experts. He also expressed support for Dr. Houman Hemmati as a potential deputy commissioner, citing Hemmati's extensive background in biotech and developing treatments for rare diseases, and his personal understanding of DMD. Stacy concluded by urging senators to confirm a commissioner who will treat patients as partners in their survival, rather than bystanders, underscoring the value of his own limited time.